Distinguishing features between SPTL-AB and SPTL-GD
| . | SPTL -AB . | SPTL-GD . |
|---|---|---|
| Immunophenotype | ||
| T-cell receptor | βF1+, TCRδ1− | βF1−, TCRδ1+ |
| T-cell phenotype | CD3+, CD4−, CD8+ | CD3+, CD4−, CD8− |
| Co-expression CD56 (%) | Absent | Common (60) |
| Histological features (architecture) | Subcutaneous | Subcutaneous and epidermal/dermal |
| Clinical features | Nodules and plaques, rarely ulceration, association with auto-immune disorders (20%) | Nodules and plaques, ulceration common |
| HPS (%) | Uncommon (17) | Common (50) |
| 5-y overall survivial, % | 82 | 11 |
| Without HPS | 91 | — |
| With HPS | 46 | — |
| Preferred terminology (WHO-EORTC) | SPTL | CGD-TCL |
| . | SPTL -AB . | SPTL-GD . |
|---|---|---|
| Immunophenotype | ||
| T-cell receptor | βF1+, TCRδ1− | βF1−, TCRδ1+ |
| T-cell phenotype | CD3+, CD4−, CD8+ | CD3+, CD4−, CD8− |
| Co-expression CD56 (%) | Absent | Common (60) |
| Histological features (architecture) | Subcutaneous | Subcutaneous and epidermal/dermal |
| Clinical features | Nodules and plaques, rarely ulceration, association with auto-immune disorders (20%) | Nodules and plaques, ulceration common |
| HPS (%) | Uncommon (17) | Common (50) |
| 5-y overall survivial, % | 82 | 11 |
| Without HPS | 91 | — |
| With HPS | 46 | — |
| Preferred terminology (WHO-EORTC) | SPTL | CGD-TCL |
HPS indicates hemophagocytic syndrome; SPTL, subcutaneous panniculitis-like T-cell lymphoma; CGD-TCL, cutaneous gamma/delta T-cell lymphoma; and —, no difference in survival of patients with or without HPS.